⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2678857 | 1.00 | — | — | |
| SCHEMBL1402641 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL11770335 | 0.98 | AR (0.35) | — | |
| SCHEMBL11547875 | 0.93 | EPHX1 (0.35) | — | |
| SCHEMBL15936736 | 0.85 | — | — | |
| Urea SCHEMBL2031932 | 0.82 | ACE (0.41) | — | |
| Valproic Acid SCHEMBL2678019 | 0.79 | CHRM1 (0.47) | — | |
| SCHEMBL3262654 | 0.78 | ACE (0.44) | — | |
| SCHEMBL8089 | 0.78 | — | — | |
| SCHEMBL7411 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158372-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2024-05-16 | — | — | US | disclosed |
| US-11780826-B2 | Bisamide sarcomere activating compounds and uses thereof | AMGEN INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20220281850-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2022-09-08 | — | — | US | disclosed |
| US-11254658-B2 | Bisamide sarcomere activating compounds and uses thereof | AMGEN INC. (US) | 2022-02-22 | — | — | US | disclosed |
| US-10723720-B2 | Bisamide sarcomere activating compounds and uses therof | AMGEN INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20200223830-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | CYTOKINETICS, INC. | 2020-07-16 | — | — | US | disclosed |
| US-20200223829-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2020-07-16 | — | — | US | disclosed |
| US-20190077793-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2019-03-14 | — | — | US | disclosed |
| US-20050261290-A1 | Novel compounds of proline and morpholine derivatives | CHENG HENGMIAO | 2005-11-24 | — | — | US | disclosed |
| EP-1434580-A2 | ALLYLAMIDES USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-07-07 | — | — | EP | disclosed |
| WO-2003030886-A2 | ALLYLAMIDES USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC (US) | 2003-04-17 | — | — | WO | disclosed |
| CN-1090186-C | HIV protease inhibitors in pharmaceutical combinations for the treatment of AIDS | MERCK & CO INC (US) | 2002-09-04 | — | — | CN | disclosed |
| CN-1176250-A | HIV protease inhibitors useful for treatment of AIDS | MERCK & CO INC (US) | 1998-03-18 | — | — | CN | disclosed |
| CN-1126469-A | HIV protease inhibitors for the treatment of AIDS | MERCK & CO INC (US) | 1996-07-10 | — | — | CN | disclosed |
| CN-1120316-A | HIV protease inhibitors in pharmaceutical combinations for the treatment of AIDS | MERCK & CO INC (US) | 1996-04-10 | — | — | CN | disclosed |